摘要
紊乱的kynurenine通路(KP)代谢与神经退行性疾病、精神疾病和癌症的进展有关。因此,通过这种途径调制的酶活性可以为这些条件提供潜在的新的治疗策略。考虑到其在KP中的显著位置,酶吲哚胺2,3-双加氧酶,犬尿氨酸3-单加氧酶和犬尿氨酸氨基转移酶,似乎是最有吸引力的目标。越来越多的人对这一途径产生了兴趣,这导致了一些有潜力的选择性的酶抑制剂的鉴定,有了有希望的临床前数据,以及几种酶晶体结构的说明,为使抑制剂活性的分子机制合理化提供了空间。该领域似乎即将产生一种或更多的抑制剂,应该能找到临床效用。
关键词: Kynurenine通路,神经变性,癌症,吲doleamine 2
Current Medicinal Chemistry
Title:Major Developments in the Design of Inhibitors along the Kynurenine Pathway
Volume: 24 Issue: 23
关键词: Kynurenine通路,神经变性,癌症,吲doleamine 2
摘要: Disrupted kynurenine pathway (KP) metabolism has been implicated in the progression of neurodegenerative disease, psychiatric disorders and cancer. Modulation of enzyme activity along this pathway may therefore offer potential new therapeutic strategies for these conditions. Considering their prominent positions in the KP, the enzymes indoleamine 2,3-dioxygenase, kynurenine 3-monooxygenase and kynurenine aminotransferase, appear the most attractive targets. Already, increasing interest in this pathway has led to the identification of a number of potent and selective enzyme inhibitors with promising pre-clinical data and the elucidation of several enzyme crystal structures provides scope to rationalize the molecular mechanisms of inhibitor activity. The field seems poised to yield one or more inhibitors that should find clinical utility.
Export Options
About this article
Cite this article as:
Major Developments in the Design of Inhibitors along the Kynurenine Pathway, Current Medicinal Chemistry 2017; 24 (23) . https://dx.doi.org/10.2174/0929867324666170502123114
DOI https://dx.doi.org/10.2174/0929867324666170502123114 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Comparison of the Structure and Biological Activities of Wild-type and Mutant Liver-targeting Peptide Modified Recombinant Human Endostatin (rES-CSP) in Human Hepatocellular Carcinoma HepG2 Cells
Protein & Peptide Letters Effects of PPARγ Agonists against Vascular and Renal Dysfunction
Current Molecular Pharmacology The Membrane-targeted Alkylphosphocholine Erufosine Interferes with Survival Signals from the Extracellular Matrix
Anti-Cancer Agents in Medicinal Chemistry Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies
Anti-Cancer Agents in Medicinal Chemistry It is All About Proteases: From Drug Delivery to In Vivo Imaging and Photomedicine
Current Medicinal Chemistry A Quantitative Proteomics Approach in the Study of MicroRNA 181a in HepG2 Cells
Current Proteomics The Effect of PDE5 Inhibitors on the Male Reproductive Tract
Current Pharmaceutical Design Pharmacogenetic Applications of the Post Genomic Era
Current Pharmaceutical Biotechnology Patented Biomarkers for the Early Detection of Ovarian Cancer
Recent Patents on Biomarkers Imaging Requirements for Personalized Medicine: The Oncologists Point of View
Current Pharmaceutical Design Non Smoking for Successful Aging: Therapeutic Perspectives
Current Pharmaceutical Design The mTOR/4E-BP1/eIF4E Signalling Pathway as a Source of Cancer Drug Targets
Current Medicinal Chemistry Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets Secreted Heat Shock Protein-90α: A More Effective and Safer Target for Anti-Cancer Drugs?
Current Signal Transduction Therapy Survivin as a Prognostic/Predictive Marker and Molecular Target in Cancer Therapy
Current Medicinal Chemistry Genetics of Bladder Malignant Tumors in Childhood
Current Genomics subject Index To Volume 3
Current Drug Targets Glycogen Synthase Kinase 3 as an Anticancer Drug Target: Novel Experimental Findings and Trends in the Design of Inhibitors
Current Pharmaceutical Design The ErbB Receptors and their Ligands in Cancer: An Overview
Current Drug Targets Discussion on the Structural Modification and Anti-tumor Activity of Flavonoids
Current Topics in Medicinal Chemistry